반응식
Cl[C:2]1[CH:11]=[CH:10][N:9]=[C:8]2[C:3]=1[C:4]1[CH:16]=[CH:15][CH:14]=[CH:13][C:5]=1[C:6](=[O:12])[NH:7]2.[NH2:17][C:18]1[CH:32]=[CH:31]C(NC(=O)C2C=CC=CC=2)=[CH:20][CH:19]=1.[CH:33]1(P(C2CCCCC2)C2C=CC=CC=2C2C(C(C)C)=CC(C(C)C)=CC=2C(C)C)CCCCC1.[CH3:67][C:68]([CH3:71])([O-])[CH3:69].[Na+]>O1CCOCC1.C([O-])(=O)C.[Pd+2].C([O-])(=O)C>[C:68]([C:71]1[CH:31]=[CH:32][C:18]([NH:17][C:2]2[CH:11]=[CH:10][N:9]=[C:8]3[C:3]=2[C:4]2[CH:16]=[CH:15][CH:14]=[CH:13][C:5]=2[C:6](=[O:12])[NH:7]3)=[CH:19][CH:20]=1)([CH3:33])([CH3:69])[CH3:67]참가 물질
반응물 4
생성물 1
시약·촉매·용매 2
반응 조건
- 온도
- 100 °C
실험 절차
1-Chloro-5H-benzo[c][1,8]naphthyridin-6-one (50 mg, 0.22 mmol), 4′-aminobenzanilide (92 mg, 0.43 mmol), palladium(II) acetate (2 mg, 0.01 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (10 mg, 0.02 mmol), and sodium tert-butoxide (83 mg, 0.87 mmol) were suspended in dioxane (2 mL), and stirred overnight at 100° C. The reaction solution was concentrated, diluted with MeOH/2M HCl/ether, and filtered. The crude product was purified directly via prep-LC-MS. The purified product was converted to the HCl salt via dissolving in MeOH, addition of 2M HCl/ether, and concentration on the Genevac to provide 119 (22 mg, 23% yield) as a dark solid. LC-MS (M+H=407, obsd.=407). 1H NMR (400 MHz, d6-DMSO): δ 10.33 (s, 1H), 9.52 (s, 1H), 8.78 (d, 1H), 8.36 (d, 1H), 8.09 (d, 1H), 7.96 (d, 2H), 7.81 (d, 2H), 7.55 (m, 5H), 7.26 (d, 2H), 6.93 (d, 1H).
후처리
- concentrationThe reaction solution was concentrated
- additiondiluted with MeOH/2M HCl/ether
- filtrationfiltered
- customThe crude product was purified directly via prep-LC-MS
- dissolutionvia dissolving in MeOH
- additionaddition of 2M HCl/ether, and concentration on the Genevac
출처 및 근거
- ORD 기록
- ord-6a53f8a5f1194d7fb3ac17f5f3ec0c9c
- 출처 데이터셋
- uspto-grants-2014_05
- 특허 번호
- US08735584B2
연결된 노트
불러오는 중…